(US and Canada) Geneial, a company advancing private, community-led genetic medicine, has been awarded a one-year pilot project through National Heart, Lung, and Blood Institute’s BioData Catalyst® (BDC) program and the Renaissance Computing Institute (RENCI) to advance AI tools to streamline the complex process of transforming biomedical data into analysis-ready formats. Geneial will collaborate with RENCI, NHLBI BioData Catalyst (BDC), and performers from the Advanced Research Projects Agency for Health (ARPA-H) Biomedical Data Fabric (BDF) Toolbox program to unlock new possibilities for precision medicine research and implementation on a broad scale.

As healthcare research relies increasingly on mapping fragmented datasets to standardized and interoperable data models, Geneial’s new AI tools will optimize and automate this process, which currently requires extensive manual effort and significant financial investment. Geneial’s technology will offer flexible, efficient conversion to current standards—such as the Global Alliance for Genomics and Health (GA4GH) Phenopackets format—while anticipating future data needs and supporting adaptable, evolving standards.

“Data standardization remains a significant challenge in precision medicine,” said Dr. Adam Hansen, CEO of Geneial. “Our collaboration with ARPA-H, NHLBI, and RENCI directly addresses this critical bottleneck, enabling researchers to focus on groundbreaking discoveries rather than laborious data management. By advancing tools that meet today’s needs and adapt to tomorrow’s, we’re substantially reduce data wrangling costs as we enhance the utility of biomedical data.”

This work aligns with Geneial’s broader vision of a global, privacy-preserving data exchange, one that allows individuals and data custodians to maintain control while connecting researchers, drug developers, and healthcare systems with harmonized, high-quality data. It marks a significant expansion of the business into AI-driven data standardization, while reinforcing Geneial’s commitment to accelerating progress in genomic medicine, making it easier for researchers to derive insights that can lead to better, more inclusive healthcare.